Therapeutic Approach

Archive: August, 2016

Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance

LOS ANGELES (August 15, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

 Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update  LOS ANGELES (August 8, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD